Next Article in Journal
Contrast-Enhanced Ultrasound LI-RADS LR-5 in Hepatic Tuberculosis: Case Report and Literature Review of Imaging Features
Previous Article in Journal
Inflammatory Bowel Diseases and Coexisting Spondyloarthritis: A Neglected and too Often Under-Reported Association by Radiologists. A Multicenter Study by Italian Research Group of Imaging in Rheumatology
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Gastroenterology Insights
Volume 11
Issue 2
10.3390/gastroent11020009
gastroent-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Laboratory Assessment of Disease Activity in Pediatric Patients with Inflammatory Bowel Disease: What’s New?

by
Rayna Shentova-Eneva
1 and
Tsvetelina Velikova
2,*
1
Department of Gastroenterology and Hepatology, Medical Faculty, University Children’s Hospital “Professor Ivan Mitev”, Medical University, 16 Akademik Ivan Evstratiev Geshov Blvd, 1606 Sofia, Bulgaria
2
Clinical Immunology, Medical Faculty, University Hospital “Lozenetz,”, Sofia University St. Kliment Ohridski, Kozyak 1 Street, 1407 Sofia, Bulgaria
*
Author to whom correspondence should be addressed.
Gastroenterol. Insights 2020, 11(2), 58-71; https://doi.org/10.3390/gastroent11020009
Submission received: 25 November 2020 / Revised: 13 December 2020 / Accepted: 18 December 2020 / Published: 21 December 2020
(This article belongs to the Section Gastrointestinal Disease)
Browse Figure
Versions Notes

Abstract

:
Laboratory tests are an integral part of both the diagnostic and follow-up algorithm of patients with inflammatory bowel disease (IBD). Their advantages over other non-invasive methods for assessing disease activity are greater objectivity than clinical activity indices and imaging studies. This review aims to analyze shortly the most common laboratory tests used to assess disease activity in pediatric patients with IBD. In addition to the conventional blood and serum markers that are not specific for gut inflammation, although routinely used, we also reviewed the established fecal markers such as calprotectin, lactoferrin, M2-pyruvate kinase, osteoprotegerin, HMGB1, chitinase 3-like 1, and the promising non-coding microRNA. In conclusion, neither marker is unique to the pediatric IBD. More clinical data are required to assess biomarkers’ full potential for diagnosis, management, and follow-up of pediatric IBD patients.

1. Introduction

Inflammatory bowel diseases (IBDs) are chronic inflammatory disorders of the gastrointestinal tract whose etiology is unknown. Pathogenesis of IBD is attributed to the complex interaction of genetic susceptibility, environmental factors (such as smoking, diet, and infections), and the gut microbiota. This results in an uncontrolled immune response leading to mucosal damage. IBDs are characterized by a relapsing and remitting course and require lifelong treatment. Therapy aims to induce remission, maintain remission, and avoid disease progression [1].
In recent years, the concept of remission has changed. Clinical remission (control of symptoms) has been replaced by the new concept of deep remission (a combination of clinical remission, biomarker remission, and mucosal healing) [2]. Endoscopic mucosal healing has become an essential therapeutic goal in IBD, associated with better prognosis and long-term outcome [3,4]. The gold standard for objective evaluation of intestinal mucosal surface is the endoscopic assessment. Still, it is challenging in the pediatric population [5,6]. Children often experience problems with fasting and bowel preparation. The procedure is invasive and requires general anesthesia and hospitalization or day-care admission [7].
Clinical indices for disease activity are useful for everyday practice. Still, they are based on the patient’s subjective complaints and, therefore, cannot be very precise [8]. A given biomarker is defined as an indicator for pathological or physiological processes and conditions in the organism. Therefore, the proper laboratory tests that serve as biomarkers are an integral part of both the diagnostic and follow-up algorithm of patients with IBD. Their advantages over other non-invasive methods for assessing disease activity are greater objectivity than clinical activity indices and abdominal ultrasound and greater accessibility than other imaging studies, especially MRI enterography [9]. This review aims to analyze shortly the most common laboratory tests used to assess disease activity in pediatric patients with IBD.

2. Conventional (Systemic) Markers of Inflammation

Conventional blood and serum markers of inflammation are widely used as non-invasive methods for objective assessment of disease activity in pediatric patients with IBD. Still, none of them are specific for gut inflammation [10].

2.1. C-Reactive Protein (CRP)

C-reactive protein (CRP) is a pentamer with a molecular weight of 25,106 Da. It is produced in the liver and is one of the most critical acute phase proteins in the human body. It was first isolated by Tillett and Francis [11] in patients with pneumonia. Its name was derived from its association with pneumococcal C-polysaccharide. Under normal conditions, hepatocytes produce low amounts of CRP (<1 mg/L). Upon stimulation, as in the presence of active inflammation, this production increases due to the effects of interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and interleukin-1β (IL-1β), and can reach peak levels of up to 350–400 mg/L [12]. Elevated levels are usually measured at hour 6 of the respective stimulus. Its plasma half-life is 19 h and is conditioned by the synthesis rate and not by the protein’s degradation [13]. Upon elimination of the stimulus, the concentration of circulating CRP decreases rapidly, almost commensurately with its plasma clearance level.
Elevated CRP levels are not specific to IBD and occur in several other conditions such as viral and bacterial infections, autoimmune diseases, malignancies, etc. [14]. In mild inflammation and viral infections, CRP levels are in the range of 10–40 mg/L. In severe active inflammation and bacterial infections, they are usually in the range of 50–200 mg/L. Extremely high levels >200–250 mg are rare and are found in severe conditions and burns [12]. CRP is an indicator with a proven role in the diagnosis and follow-up of patients with IBD. However, there is significant inter- and intraindividual heterogeneity in its synthesis. Elevated CRP levels are more common in patients with active Crohn’s disease (CD) than in those with ulcerative colitis (UC) [15]. Possible explanations for this difference are the nature of the inflammation in the respective disease—transmural in CD and mucosal in UC and the higher concentration of IL-6 in patients with CD [12,16]. Gross et al. [16] found that 68.5% of patients with CD had serum concentrations of IL-6 ≥ 4 U/L compared to 21.7% of patients with UC and 0% of healthy controls. Florin et al. [17] found significant differences in CRP levels also between patients with CD. They found that approximately 10% of patients with active CD had CRP levels <10 mg/L. This group of patients was characterized by a low body mass index and isolated terminal ileum involvement. In recent years, differences in CRP production have been explained by genetic polymorphisms in the CRP gene, which is located on the long arm of chromosome 1 (1q23–24). However, various studies in this regard are contradictory [12,18,19].

2.2. Erythrocyte Sedimentation Rate (ESR)

The rate at which red blood cells migrate through the plasma and precipitate in a special vertical tube within 1 h is called the erythrocyte sedimentation rate (ESR). Under the influence of prosedimentation factors (fibrinogen), erythrocytes clump together and precipitate faster in the presence of inflammation. Elevated ESR is not specific to IBD and is found in many other conditions. In addition, ESR is influenced by age, sex, the presence of anemia, pregnancy, etc. [20]. Compared to CRP, ESR rises more smoothly and drops more slowly, which makes this indicator less suitable for monitoring changes in the activity of the respective disease. Nevertheless, ESR is a proven and widely used marker of IBD activity [12,21].

2.3. Fibrinogen

Fibrinogen is an acute-phase protein that is produced in the liver. It has two essential roles in the body—it is involved in coagulation and is part of the acute-phase response to tissue inflammation and damage [22]. Fibrinogen levels are elevated in patients with IBD [23,24]. Numerous studies have shown that fibrinogen is elevated in both disease activity and remission [25,26,27]. According to other authors, there is a positive correlation between fibrinogen levels and IBD activity [28]. The disadvantages of fibrinogen as a marker of IBD activity are its relatively slow response time and the long plasma half-life of 3–4 days [22].

2.4. Albumin

Albumin is a negative acute-phase protein, and, in the presence of inflammation, as in IBD, its levels decrease. Serum albumin levels correlate with the severity of endoscopic findings in both CD and UC [29,30]. However, it should be borne in mind that hypoalbuminemia is not specific to IBD and occurs in other diseases and conditions such as malnutrition, protein-losing enteropathy, celiac disease, and others [12].

2.5. White Blood Cell Count

White blood cell count rises as part of the acute phase response in patients with IBD activity. Leukocytosis is not specific to IBD and can be found in other inflammatory conditions and in severe stress. It is crucial to keep in mind that white blood cell count may also be affected by IBD treatment. There may be a rise with corticosteroid treatment and a drop-down with thiopurine treatment [12].

2.6. Platelet Count

In 1968, Morowitz et al. [31] first described an increase in platelet count in patients with clinically active IBD. In 1991, Harries et al. [32] suggested a platelet count test as a simple diagnostic test to differentiate between IBD and infectious diarrhea. Currently, reactive thrombocytosis (defined as a platelet count >450 thousand/L) is considered one of the characteristic laboratory abnormalities in newly diagnosed or exacerbated IBD [33]. The reasons for this condition are not completely clear. According to some authors, such as Shen et al. [34], it is related to the organism’s non-specific response to the inflammatory process and the overall increased activity of the cells and tissues.
According to other authors such as Kulnigg-Dabsch et al. [35], anemia in IBD results in increased erythropoietin production, which is a structural homolog of thrombopoietin. Megakaryopoiesis is stimulated, and thrombocytosis occurs. Significant thrombocytosis (>600 thousand/L) is commonly seen in active ulcerative colitis, less frequently in active CD involving the colon, and less commonly in active CD involving mainly the terminal ileum [36]. Along with the increase in platelet count, a decrease in mean platelet volume (MPV) is observed, which is why MPV has also been studied as a potential marker for assessing IBD activity. However, the results are contradictory [37]. It is important to note that thrombocytosis contributes to the tendency to hypercoagulability in patients with IBD and the possibility of microclot formation [38,39,40].

3. Fecal Markers of Inflammation

Fecal markers are a heterogeneous group of biological substances formed by the inflamed intestinal mucosa or pass through it and enter the intestinal lumen and feces, where they can be measured [41]. The advantage of fecal markers of inflammation over blood markers is that they provide information about the inflammatory process’s location, particularly the location along the gastrointestinal tract. Still, they also are not specific to IBD [42,43].

3.1. Fecal Alpha-1 Antitrypsin

Alpha-1 antitrypsin (AAT) is a serum protease inhibitor that constrains and modifies the effect of 90% of serum proteolytic enzymes—trypsin, neutrophil elastase, pancreatic elastase, serine protease, collagenase, kallikrein, and factor-8. Unlike other major serum proteins, it is highly resistant to intestinal protein degradation and is excreted intact in the feces [44]. In the presence of intestinal inflammation, due to increased permeability and impaired mucosal integrity, AAT excretion in the feces increases [45]. Elevated fecal AAT levels are found in protein-losing enteropathies, celiac disease, giardiasis, IBD, malignancies, etc. Various studies have been performed in patients with IBD to assess the relationship between fecal AAT concentration and disease activity. However, the results are contradictory [46,47,48,49].

3.2. Fecal Lactoferrin

Lactoferrin is an 80 kDa iron-binding protein. It is secreted by specific epithelial cells and can be found in various bodily fluids, including serum, tears, synovial fluid, and breast milk [50,51]. Besides, lactoferrin is the major protein in the secondary granules of polymorphonuclear granulocytes. It has both proinflammatory and anti-inflammatory properties [52]. In the presence of intestinal inflammation, polymorphonuclear cells infiltrate into the intestinal mucosa and subsequently enter the intestinal lumen, which results in a rise of the concentration of lactoferrin in the feces [53].
Fecal lactoferrin (FL) is stable for up to 5 days at room temperature. Its presence can be determined by qualitative and quantitative tests [54,55]. FL testing is used both in the diagnosis and in the follow-up of patients with IBD [54,56]. Its limitations as a marker in IBD are related to its non-specificity—elevated levels of FL are also found in various intestinal infections, during the administration of non-steroidal anti-inflammatory drugs (NSAIDs), in malignant intestinal diseases, etc.; to the fact that, in addition to neutrophils, it is secreted by other cells; and to the evidence of its lower accuracy as a laboratory indicator compared to fecal calprotectin (FC), a fecal marker that is most widely studied and used in clinical practice [57,58,59].

3.3. Fecal Calprotectin

Calprotectin is a small calcium and zinc-binding protein with a molecular weight of 36 kDa [60]. It was discovered in 1980 by Magne Fagerhol et al. and was initially named the L1 protein or leukocyte-derived L1 protein [61]. The name calprotectin was proposed after it was found to have antimicrobial (protective) properties and given its ability to bind calcium [62]. Calprotectin is a heterocomplex consisting of one light (8 kDa) and two heavy chains (14 kDa each), which are non-covalently linked [63]. It belongs to the group of S100 proteins [64]. S100 are low molecular weight proteins that bind calcium and participate in many intracellular and extracellular processes, including enzyme activation, cell growth, differentiation, inflammatory responses, etc. [65]. The genes encoding calprotectin and other S100 proteins are located in the long arm of chromosome 1q12–q21 [64].
Calprotectin is found predominantly in neutrophils, monocytes, and macrophages [66,67,68]. It makes up 5% of the total amount of protein and approximately 60% of the cytosolic proteins in neutrophils. In monocytes, it is approximately 1.6% of the total amount of protein [61,63]. Calprotectin features antimicrobial and antifungal activity [62,69]. Additionally, it inhibits cell growth and induces cell death in specific cell types such as fibroblasts, some tumor cells, and others [70,71,72]. Thus, as a result of its biological functions, it participates actively in regulating the inflammatory process. Upon stimulation, neutrophils and monocytes secrete calprotectin extracellularly [66]. Its extracellular release is also observed in cell destruction or cell death [73]. Typically, calprotectin can be found in plasma, synovial fluid, cerebrospinal fluid, saliva, urine, and feces [74,75]. An elevated level of calprotectin has been observed with increased accumulation of inflammatory cells in the course of an infection, some other inflammatory process, or malignancies [74].
In intestinal inflammation, the concentration of calprotectin in the feces is proportional to the degree of neutrophil infiltration into the intestinal wall, and the number of neutrophils in the intestinal lumen [76]. Elevated levels of FC are found in IBD, polyps, intestinal malignancies, intestinal infections, and others [75,76,77]. The use of NSAIDs and proton pump inhibitors and bleeding outside the gastrointestinal tract also elevates FC levels. Its concentration is physiologically higher in early childhood [77]. FC is homogeneously distributed in feces and is stable for up to 1 week at room temperature [75]. Significant differences in its concentration may be observed if measured sequentially on different days [78].
In recent years, FC has been widely studied as a marker in IBD. Its importance for diagnosing IBD, its role in monitoring patients with IBD to assess the disease activity and the response to therapy, and its ability to predict clinical recurrence or mucosal healing have been studied. The results generally show that FC helps to diagnose patients with IBD and facilitate patient follow-up by providing information on disease activity, the presence or absence of response to treatment, remission achieved, or recurrence risk [79]. The specific sensitivity and specificity of this indicator and the different correlation indices vary widely between the studies and depend on the studied population and the cut-off values used [43,79,80].

3.4. M2-Pyruvate Kinase

It was shown that fecal M2-PK concentrations are elevated in colorectal carcinoma and intestinal inflammation [81], indicating increased cell turnover. Moreover, it is believed that intestinal epithelial cells may be resistant to apoptosis by upregulation of M2-PK via the Bcl-xl pathway in CD [82].
Czub et al. tested fecal M2-PK levels in 107 Polish children with IBD (75 with UC, 32 with CD, and 35 healthy controls) [83]. M2-PK levels in stool samples were higher in children with IBD and were associated with the pediatric Crohn’s disease activity index (PCDAI). While mean M2-PK levels were higher in those with active disease, 47% of children with IBD deemed to be in remission still had elevated M2-PK levels. Another study, conducted by Day et al. (2012), also demonstrated higher fecal M2-PK in CD children but without an established association with PCDAI scores or serum inflammatory markers, such as fecal S100A12 [84]. Interestingly, children with ileocolonic disease appeared to have higher concentrations of M2-PK than those with isolated colonic or ileal disease.
Enhanced fecal M2-PK levels have also been seen in children with active UC [85]. Furthermore, M2-PK was superior to other markers (calprotectin, S100A12, and lactoferrin). In a 2014 study by Czub et al., when using Truelove–Witts score for UC patients and PCDAI for CD patients, M2-PK concentration was identified as inferior to calprotectin, especially in children in IBD remission. However, on the contrary, are the findings made by Roszak et al. [86] who suggest that M2-PK is a more sensitive marker to assess disease activity in pediatric UC or CD than calprotectin and lactoferrin. More studies are needed to explain this difference in this field.

3.5. Osteoprotegerin

Osteoprotegerin (OPG) belongs to the TNF superfamily and represents a cytokine receptor. A broad variety of cell types, distinct from those that produce calprotectin and lactoferrin, produce OPG—osteoblasts, B lymphocytes, dendritic cells, stromal bone marrow cells, epithelial cells, and monocytes/macrophages [82]. It is thought that OPG promotes bone formation, contrary to inflammatory cytokines such as IL-1, TNFα, etc. This is especially important for pediatric IBD, where the increased risk of fracture associated with the disease is described. Nevertheless, the role of OPG produced in the intestinal mucosa on bone loss in the IBD remains unresolved. Besides its bone turnover role, OPG exerts functions in IBD pathogenesis related to local and systemic inflammation [82].
A limited number of studies have shown that OPG is a useful biomarker of inflammation in pediatric IBD. Nahidi et al. [87] measured OPG in children with CD. Serum, stool, and biopsy samples showed dramatically rise in the OPG levels. Moreover, the remission after induction therapy dropped the serum and fecal levels substantially. Those children with isolated colonic CD had higher levels than those with ileocolonic form. However, serum and fecal of OPG did not correlate with the PCDAI scores, but with CRP and fecal S100A12 before and not after treatment.
Regarding pediatric UC, Sylvester et al. [88] assessed fecal OPG as a predictive marker for children’s treatment response. They demonstrated that patients with failed first-line corticosteroid therapy or who required infliximab or colectomy had elevated fecal OPG. Thus, OPG was superior to lactoferrin or S100A12 in predicting the treatment response. This gives us hope that it can be used for follow up and monitoring pediatric IBD patients. An important note is that OPG is more easily degraded at room temperature in the stool, and special preservation and storage conditions should be applied.

3.6. High Mobility Group Box Protein 1

High mobility group box protein 1 (HMGB1) is released by the immune cells during inflammation. Vitali et al. (2011) demonstrated that HMGB1 was significantly elevated in fecal and biopsy samples of children with IBD compared to healthy controls [89]. Furthermore, fecal HMGB1 correlated with FC, even though the cell sources for the two proteins are different. HMGB1 also correlates with mucosal changes in children with remission and active disease (moderate correlation with simple endoscopic score for Crohn’s disease (SES-CD) and endoscopic Mayo subscore. However, HMGB1 levels and activity indices (Crohn’s disease activity index (CDAI) and a partial UC Mayo score) did not correlate.
Accordingly, it is suggested that fecal HMGB1 as a marker of subclinical gut inflammation and a novel biomarker of mucosal healing [40], taking into account that it can be elevated in enteric infection as well [41]. It was also sown in animal models that HMGB1 could be treated with dipotassium glycyrrhizate or ethyl pyruvate, which should be further investigated in human IBD [82].

3.7. Chitinase 3-Like 1

Chitinase 3-like 1 (CHI3L1) expression in colonocytes and lamina propria macrophages is upregulated as a factor that facilitates bacterial penetration and adhesion to epithelial cells [82]. This protein was found elevated not only in adults with IBD but also in children. Aomatsu et al. [90] showed a marked increase of fecal CHI3L1 in children with IBD. Even a cut-off of 13.7 ng/g in fecal samples could differentiate between children’s IBD and controls with 84.7% sensitivity and 88.9% specificity. CHI3L1 levels were also shown to correlate with the scores for endoscopic severity of UC and CD, and with FC levels. The concentrations of the protein were dropped down in pediatric patients in remission.
Interestingly, CHI3L1 may be involved in neoplastic inflammation-related changes of the colonic epithelial cells in addition to his alleged role in IBD [91]. This, mainly, should be investigated further since the chronic inflammation accompanying IBD affects children early in their lives and may increase the cancerogenic susceptibility.
An overview of the fecal and serum biomarkers available for pediatric IBD is shown in Figure 1.
It is worth mentioning that the most recent guidelines of ESPGHAN, NASPGHAN, and ECCO recommend the routine use of laboratory parameters not only for the diagnosis [92,93] but also for the management of pediatric IBD [94,95,96].
Blood tests (CBC, albumin, CRP, ESR, etc.) should be performed regularly by pediatric patients with UC depending on their symptoms and therapy and at least every three months while on immunosuppressive medications and at least every 6–12 months otherwise. Measurement of FC is advisable to verify mucosal healing in the patients in clinical remission, as a significant endoscopic activity may be present in 20% of children with PUCAI < 10. In addition, values of FC > 250 mg/g accurately predict mucosal inflammation and may select those patients who require endoscopic assessment and therapy escalation [94,95].
Regarding pediatric CD, repeat FC measurements in patients in clinical remission make it possible to identify a disease flare early, as FC increase precedes the disease relapse by 2–3 months. The combination of FC and CRP is superior in detecting endoscopic disease activity than FC alone. On the other side, the constellation of clinical remission, FC < 250 µg/g and CRP < 5 mg/L is the best non-invasive test for mucosal healing and can be used for treatment target [96].
The available information regarding the performance of all the discussed systemic and fecal markers for detecting intestinal inflammation and disease activity is presented in Table 1, when applicable.

4. Novel Promising Biomarkers in Pediatric Inflammatory Bowel Disease

In addition to the well-established biomarkers for pediatric IBD management, some promising markers are likely to represent different cell origins and aspects of the IBD immunopathogenesis. Currently, no single novel marker appears as a highly specific, sensitive, diagnostic, and prognostic IBD predictor [82]. However, novel biomarkers must be tested comprehensively to ascertain their role in diagnosing, follow-up, and predicting disease behavior in children.

miRNAs in Pediatric IBD

The role of miRNAs is crucial to the development and homeostasis of the intestines. Many studies have shown that mature miRNAs are involved in forming proper intestinal structure and function [103,104]. Moreover, without specific miRNAs, the mouse’s intestinal epithelia lack proper barrier integrity goblet cells and simultaneously induce inflammation, which reminisces of IBD. Studies have shown so far that in various pathologies, including IBD, colorectal carcinoma [105], etc., miRNA expression is disrupted.
In adults with UC and CD, alterations in intestinal microRNAs have been identified. In children with IBD, however, the data on microRNA expression associated with colitis is still insufficient. In line with this, identifying molecular disorders can also lead to better management and care of pediatric IBDs. Moreover, since children frequently have a more severe phenotype, pediatric IBD pathogenesis can be molecularly distinct from adult IBD.
Zahm et al. (2014) researched specific rectal and serum microRNAs in pediatric IBD [106]. The results showed that the most abundant miRNAs were miR-21, miR-142-3p, comprising more than 20% of the overall miRNA of the rectal mucosal biopsies. Four miRNAs (miR-192, miR-194, miR-200b, and miR-375) were downregulated, and four (miR-21, miR-142-3p and miR-146a, and let-7i) were considerably increased in pediatric UC. In L2 CD patients, in comparison to controls, only miR-375 and miR-21 have been substantially modified [106]. Furthermore, in UC patients receiving 6-mercaptopurine or methotrexate immunomodulators, significant correlations were found between rectal miRNAs and the treatment. In contrast with UC patients lacking immunomodulators, these were seen to have substantially elevated miR-375 and miR-192. There was no correlation between miRNAs levels and the time needed for establishing the diagnosis of IBD [106].
It remains a struggle to distinguish UC from L2 CD in the pediatric population. Even after endoscopy, the diagnosis could not be straightforward. Compared CD to UC, the rectal miR-24 was the only microRNA altered between IBD subtypes, increased almost one and a half times in UC. On this basis, rectal miR-24 could correctly identify 84.2% of patients, with a sensitivity of 83.3% and specificity of 85.7%. The other investigated miRNAs, such as MiR-192, miR-142-3p, and miR-21, correctly distinct 78.72%, 72.34%, and 72.34% of patients, respectively. However, serum and rectal miRNAs did not show a correlation in this study. Further studies are required to confirm miRNA tissue biomarkers of IBD, L2 CD against UC in infants [106].
Previously, Zahm et al. (2011) reported rectal miRNAs consistent with colitis in children with IBD and controls. In children with IBD, miR-192 or miR-21 have been identified as elevated in pediatric CD [107]. On this basis, they suggested that circulating miRNAs are potential biomarkers of pediatric CD. Furthermore, the findings and preliminary research exploring miRNA shifts in adult IBD are broadly overlapping. Additionally, miRNAs are likely to contribute through targeted disease-related mRNAs to the pathogenesis of IBD.

5. Conclusions

In the ideal variant, the biomarker will show a particular condition and the severity of the condition. Several promising fecal, serum and mucosal biomarkers for IBD have been reported to date. Neither marker is unique to the pediatric IBD.
However, a number of promising new biomarkers were identified, and a part of the most promising new markers was described in this review. More clinical trials are required to assess the full potential of biomarkers for diagnosis, management, and follow-up of pediatric IBD patients. Although such evaluations include particular biomarkers, comparative assessments between new and established biomarkers are still needed, in addition to the possibility for novel biomarkers to affect clinical treatment.

Author Contributions

Writing—original draft preparation, R.S.-E.; writing—review and editing, R.S.-E. and T.V.; visualization, T.V. Both authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Liverani, E.; Scaioli, E.; Digby, R.J.; Bellanova, M.; Belluzzi, A. How to predict clinical relapse in inflammatory bowel disease patients. World J Gastroenterol. 2016, 22, 1017–1033. [Google Scholar] [CrossRef] [PubMed]
  2. Orlando, A.; Guglielmi, F.W.; Cottone, M.; Orlando, E.; Romano, C.; Sinagra, E. Clinical implications of mucosal healing in the management of patients with inflammatory bowel disease. Dig. Liver Dis. 2013, 45, 986–991. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  3. Pineton de Chambrun, G.; Peyrin-Biroulet, L.; Lémann, M.; Colombel, J.F. Clinical implications of mucosal healing for the management of IBD. Nat. Rev. Gastroenterol. Hepatol. 2010, 7, 15–29. [Google Scholar] [CrossRef] [PubMed]
  4. Fiorino, G.; Cesarini, M.; Indriolo, A.; Malesci, A. Mucosal healing in ulcerative colitis: Where do we stand? Curr. Drug Targets 2011, 12, 1417–1423. [Google Scholar] [CrossRef] [PubMed]
  5. Vieira, A.; Fang, C.; Rolim, E.; Klug, W.; Steinwurz, F.; Rossini, L.G.B.; Candelária, P.A. Inflammatory bowel disease activity assessed by fecal calprotectin and lactoferrin: Correlation with laboratory parameters, clinical, endoscopic and histological indexes. BMC Res. Notes 2009, 2, 221. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  6. Gisbert, J.; McNicholl, A. Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease. Dig. Liver Dis. 2009, 41, 56–66. [Google Scholar] [CrossRef] [PubMed]
  7. Lehmann, F.S.; Burri, E.; Beglinger, C. The role and utility of faecal markers in inflammatory bowel disease. Therap. Adv. Gastroenterol. 2015, 8, 23–36. [Google Scholar] [CrossRef] [Green Version]
  8. Aomatsu, T.; Yoden, A.; Matsumoto, K.; Kimura, E.; Inoue, K.; Andoh, A.; Tamai, H. Fecal calprotectin is a useful marker for disease activity in pediatric patients with inflammatory bowel disease. Dig. Dis. Sci. 2011, 56, 2372–2377. [Google Scholar] [CrossRef]
  9. Nakov, V. Surrogate markers of intestinal inflammation—Fecal calprotectin. Bulg. Med. J. 2012, 6, 26–30. [Google Scholar]
  10. Xiang, J.; Ouyang, Q.; Li, G.; Xiao, N. Clinical value of fecal calprotectin in determining disease activity of ulcerative colitis. World J. Gastroenterol. 2008, 7, 53–57. [Google Scholar] [CrossRef]
  11. Tillet, W.S.; Francis, T. Serological reactions in pneumonia with a non-protein somatic fraction of the pneumococcus. J. Exp. Med. 1930, 52, 561–571. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  12. Vermeire, S.; Van Assche, G.; Rutgeerts, P. Laboratory markers in IBD: Useful, magic, or unnecessary toys? Gut 2006, 55, 426–431. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  13. Vigushin, D.M.; Pepys, M.B.; Hawkins, P.N. Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease. J. Clin. Invest. 1993, 91, 1351–1357. [Google Scholar] [CrossRef]
  14. Pepys, M.B.; Hirschfield, G.M. C-reactive protein: A critical update. J. Clin. Invest. 2003, 111, 1805–1812. [Google Scholar] [CrossRef] [PubMed]
  15. Saverymuttu, S.H.; Hodgson, H.J.; Chadwick, V.S.; Pepys, M.B. Differing acute phase responses in Crohn’s disease and ulcerative colitis. Gut 1986, 27, 809–813. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  16. Gross, V.; Andus, T.; Caesar, I.; Roth, M.; Schölmerich, J. Evidence for continuous stimulation of interleukin-6 production in Crohn’s disease. Gastroenterology 1992, 102, 514–519. [Google Scholar] [CrossRef]
  17. Florin, T.H.; Paterson, E.W.; Fowler, E.V.; Radford-Smith, G.L. Clinically active Crohn’s disease in the presence of a low C-reactive protein. Scand. J. Gastroenterol. 2006, 41, 306–311. [Google Scholar] [CrossRef] [PubMed]
  18. Carlson, C.S.; Aldred, S.F.; Lee, P.K.; Tracy, R.P.; Schwartz, S.M.; Rieder, M.; Liu, K.; Williams, O.D.; Iribarren, C.; Lewis, E.C.; et al. Polymorphisms within the C-reactive protein (CRP) promoter region are associated with plasma CRP levels. Am. J. Hum. Genet. 2005, 77, 64–77. [Google Scholar] [CrossRef] [Green Version]
  19. Willot, S.; Vermeire, S.; Ohresser, M.; Rutgeerts, P.; Paintaud, G.; Belaiche, J.; DeVos, M.; VanGossum, A.; Franchimont, D.; Colombel, J.F.; et al. C-reactive protein gene polymorphisms are not associated with biological or clinical response to infliximab in Crohn’s disease. Gastroenterology 2005, 128, A311. [Google Scholar]
  20. Mendoza, J.L.; Abreu, M.T. Biological markers in inflammatory bowel disease: Practical consideration for clinicians. Gastroenterol. Clin. Biol. 2009, 33, S158–S173. [Google Scholar] [CrossRef]
  21. Iskandar, N.; Ciorba, M. Biomarkers in inflammatory bowel disease: Current practices and recent advances. Transl. Res. 2012, 159, 313–325. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  22. Kilicarslan, A.; Uysal, A.; Roach, E. Acute phase reactants. Acta Medica 2013, 2, 2–7. [Google Scholar]
  23. Novacek, G.; Miehsler, W.; Kapiotis, S.; Katzenschlager, R.; Speiser, W.; Vogelsang, H. Thromboembolism and resistance to activated protein C in patients with inflammatory bowel disease. Am. J. Gastroenterol. 1999, 94, 685–690. [Google Scholar] [CrossRef] [PubMed]
  24. Udvardy, M.; Altorjay, I.; Palatka, K. Hematologic aspects of inflammatory bowel diseases. Orvosi Hetilap 2001, 142, 883–886. [Google Scholar]
  25. Hayat, M.; Ariens, R.A.; Moayyedi, P.; Grant, P.J.; O’Mahony, S. Coagulation factor XIII and markers of thrombin generation and fibrinolysis in patients with inflammatory bowel disease. Eur. J. Gastroenterol. Hepatol. 2002, 14, 249–256. [Google Scholar] [CrossRef]
  26. Novotny, D.A.; Rubin, R.J.; Slezak, F.A.; Porter, J.A. Arterial thromboembolic complications of inflammatory bowel disease. Report of three cases. Dis. Colon Rectum 1992, 35, 193–196. [Google Scholar] [CrossRef]
  27. Swiatkowski, M.; Grad, K.; Klopocka, M.; Budzyński, J.; Zekanowska, E.; Kotschy, M. Blood coagulation activation in patients with ulcerative colitis. Pol. Arch. Med. Wewn. 2000, 103, 47–51. [Google Scholar]
  28. Yazici, A.; Senturk, O.; Aygun, C.; Celebi, A.; Caglayan, C.; Hulagu, S. Thrombophilic risk factors in patients with inflammatory bowel disease. Gastroenterol. Res. 2010, 3, 112–119. [Google Scholar] [CrossRef] [Green Version]
  29. Holmquist, L.; Ahren, C.; Fallstrom, S.P. Clinical disease activity and inflammatory activity in the rectum in relation to mucosal inflammation assessed by colonoscopy. A study of children and adolescents with chronic inflammatory bowel disease. Acta Paediatr. Scand. 1990, 79, 527–534. [Google Scholar] [CrossRef]
  30. Moran, A.; Jones, A.; Asquith, P. Laboratory markers of colonoscopic activity in ulcerative colitis and Crohn colitis. Scand. J. Gastroenterol. 1995, 30, 356–360. [Google Scholar] [CrossRef]
  31. Morowitz, D.A.; Allen, L.W.; Kirsner, J.B. Thrombocytosis in chronic inflammatory Bowel disease. Ann. Intern. Med. 1968, 68, 1013–1021. [Google Scholar] [CrossRef] [PubMed]
  32. Harries, A.D.; Beeching, N.J.; Rogerson, S.J.; Nye, F.J. The platelet count as a simple measure to distinguish inflammatory bowel disease from infective diarrhoea. J. Infect. 1991, 22, 247–250. [Google Scholar] [CrossRef]
  33. Talstad, I.; Rootwelt, K.; Gjone, E. Thrombocytosis in ulcerative colitis and Crohn’s disease. Scand. J. Gastroenterol. 1973, 8, 135–138. [Google Scholar] [CrossRef] [PubMed]
  34. Shen, J.; Ran, Z.H.; Zhang, Y.; Cai, Q.; Yin, H.M.; Zhou, X.T.; Xiao, S.D. Biomarkers of altered coagulation and fibrinolysis as measures of disease activity in active inflammatory bowel disease: A gender-stratified, cohort analysis. Thromb. Res. 2009, 123, 604–611. [Google Scholar] [CrossRef]
  35. Kulnigg-Dabsch, S.; Evstatiev, R.; Dejaco, C.; Gasche, C. Effect of iron therapy on platelet counts in patients with inflammatory bowel disease-associated anemia. PLoS ONE 2012, 7, 34520. [Google Scholar] [CrossRef] [Green Version]
  36. Collins, C.E.; Rampton, D.S. Review article: Platelets in inflammatory bowel disease—Pathogenetic role and therapeutic implications. Aliment. Pharmacol. Ther. 1997, 11, 237–247. [Google Scholar] [CrossRef] [Green Version]
  37. Fengming, Y.; Jianbing, W. Biomarkers of inflammatory bowel disease. Dis. Markers 2014, 2014, 710915. [Google Scholar] [CrossRef]
  38. Collins, C.E.; Rampton, D.S. Platelet dysfunction: A new dimension in inflammatory bowel disease. Gut 1995, 36, 5–8. [Google Scholar] [CrossRef] [Green Version]
  39. Danese, S.; De la Motte, C.; Fiocchi, C. Platelets in inflammatory bowel disease: Clinical, pathogenic, and therapeutic implications. Am. J. Gastroenterol. 2004, 99, 938–945. [Google Scholar] [CrossRef]
  40. Dong, W.G.; Liu, S.P.; Zhu, H.H.; Luo, H.S.; Yu, J.P. Abnormal function of platelets and role of Angelica sinensis in patients with ulcerative colitis. World J. Gastroenterol. 2004, 10, 606–609. [Google Scholar] [CrossRef]
  41. Poullis, A.; Foster, R.; Mendall, M.A. Proton pump inhibitors are associated with elevation of faecal calprotectin and may affect specificity. Eur. J. Gastroenterol. Hepatol. 2003, 15, 573–574. [Google Scholar] [CrossRef] [PubMed]
  42. Poullis, A.; Foster, R.; Northfield, T.C.; Mendall, M.A. Review article: Faecal markers in the assessment of activity in inflammatory bowel disease. Aliment. Pharmacol. Ther. 2002, 16, 675–681. [Google Scholar] [CrossRef] [PubMed]
  43. Wright, E.K. Calprotectin or lactoferrin: Do they help. Dig. Dis. 2016, 34, 98–104. [Google Scholar] [CrossRef] [PubMed]
  44. Sharp, H.L. The current status of alpha-1-antityrpsin, a protease inhibitor, in gastrointestinal disease. Gastroenterology 1976, 70, 611–621. [Google Scholar] [CrossRef]
  45. Kosek, M.; Haque, R.; Lima, A. Fecal markers of intestinal inflammation and permeability associated with the subsequent acquisition of linear growth deficits in infants. Am. J. Trop. Med. Hyg. 2013, 88, 390–396. [Google Scholar] [CrossRef] [Green Version]
  46. Fischbach, W.; Becker, W.; Mössner, J.; Koch, W.; Reiners, C. Faecal alpha-1-antitrypsin and excretion of 111indium granulocytes in assessment of disease activity in chronic inflammatory bowel diseases. Gut 1987, 28, 386–393. [Google Scholar] [CrossRef] [Green Version]
  47. Grill, B.B.; Hillemeier, A.C.; Gryboski, J.D. Fecal alpha 1-antitrypsin clearance in patients with inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 1984, 3, 56–61. [Google Scholar] [CrossRef]
  48. Meyers, S.; Wolke, A.; Field, S.P.; Feuer, E.J.; Johnson, J.W.; Janowitz, H.D. Fecal alpha-1-antitrypsin measurement: An indicator of Crohn’s disease activity. Gastroenterology 1985, 89, 13–18. [Google Scholar] [CrossRef]
  49. Thomas, D.W.; Sinatra, F.R.; Merritt, R.J. Fecal α-1-antitrypsin excretion in young people with Crohn’s disease. J. Pediatr. Gastroenterol. Nutr. 1983, 2, 491–496. [Google Scholar] [CrossRef]
  50. Masson, P.L.; Heremans, J.F.; Dive, C. An iron-binding protein common to many external secretions. Clin. Chim. Acta 1966, 14, 735–739. [Google Scholar] [CrossRef]
  51. Masson, P.L.; Heremans, J.F.; Schonne, E. Lactoferrin, an iron-binding protein in neutrophilic leukocytes. J. Exp. Med. 1969, 130, 643–658. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  52. Mason, D.Y.; Taylor, C.R. Distribution of transferrin, ferritin, and lactoferrin in human tissues. J. Clin. Pathol. 1978, 31, 316–327. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  53. Desai, D.; Faubion, W.A.; Sandborn, W.J. Review article: Biological activity markers in inflammatory bowel disease. Aliment. Pharmacol. Ther. 2007, 25, 247–255. [Google Scholar] [CrossRef] [PubMed]
  54. Sugi, K.; Saitoh, O.; Hirata, I.; Katsu, K. Fecal lactoferrin as a marker for disease activity in inflammatory bowel disease: Comparison with other neutrophil-derived proteins. Am. J. Gastroenterol. 1996, 91, 927–934. [Google Scholar]
  55. Uchida, K.; Matsuse, R.; Tomita, S.; Sugi, K.; Saitoh, O.; Ohshiba, S. Immunochemical detection of human lactoferrin in feces as a new marker for inflammatory gastrointestinal disorders and colon cancer. Clin. Biochem. 1994, 27, 259–264. [Google Scholar] [CrossRef]
  56. Schoepfer, A.; Trummler, M.; Seeholzer, P.; Seibold-Schmid, B.; Seibold, F. Discriminating IBD from IBS: Comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies. Inflamm. Bowel Dis. 2008, 14, 32–39. [Google Scholar] [CrossRef]
  57. Schroder, O.; Naumann, M.; Shastri, Y.; Povse, N.; Stein, J. Prospective evaluation of faecal neutrophil-derived proteins in identifying intestinal inflammation: Combination of parameters does not improve diagnostic accuracy of calprotectin. Aliment. Pharmacol. Ther. 2007, 26, 1035–1042. [Google Scholar] [CrossRef]
  58. Silberer, H.; Kuppers, B.; Mickisch, O.; Baniewicz, W.; Drescher, M.; Traber, L.; Kempf, A.; Schmidt-Gayk, H. Fecal leukocyte proteins in inflammatory bowel disease and irritable bowel syndrome. Clin. Lab. 2005, 51, 117–126. [Google Scholar]
  59. Vrabie, R.; Kane, S. Noninvasive markers of disease activity in inflammatory bowel disease. Gastroenterol. Hepatol. 2014, 10, 576–584. [Google Scholar]
  60. Dale, I.; Fagerhol, M.K.; Naesgaard, I. Purification and partial characterization of a highly immunogenic human leukocyte protein, the L1 antigen. Eur. J. Biochem. 1983, 134, 1–6. [Google Scholar] [CrossRef]
  61. Fagerhol, M.K.; Dale, I.; Andersson, T. Release and quantitation of a leucocyte derived protein (LI). Scand. J. Haematol. 1980, 24, 393–398. [Google Scholar] [CrossRef]
  62. Steinbakk, M.; Naess-Andresen, C.F.; Lingaas, E.; Dale, I.; Brandtzaeg, P. Antimicrobial actions of calcium binding leucocyte L1 protein, calprotectin. Lancet 1990, 336, 763–765. [Google Scholar] [CrossRef]
  63. Fagerhol, M.K.; Andersson, K.B.; Naess-Andresen, C.F.; Brandtzaeg, P.; Dale, I.; Smith, V.L.; Dedman, J.R. Calprotectin (the L1 leukocyte protein). In Stimulus Response Coupling: The Role of Intracellular Calcium-Binding Proteins; Smith, V.L., Dedman, J.R., Eds.; CRC Press: Boca Raton, FL, USA, 1990; pp. 187–210. [Google Scholar]
  64. Dorin, J.R.; Emslie, E.; Van Heyningen, V. Related calcium-binding proteins map to the same subregion of chromosome 1q and to an extended region of synteny on mouse chromosome 3. Genomics 1990, 8, 420–426. [Google Scholar] [CrossRef]
  65. Donato, R. Intracellular and extracellular roles of S100 proteins. Microsc. Res. Tech. 2003, 60, 540–551. [Google Scholar] [CrossRef] [PubMed]
  66. Dale, I.; Brandtzaeg, P.; Fagerhol, M.K.; Scott, H. Distribution of a new myelomonocytic antigen (L1) in human peripheral blood leukocytes. Immunofluorescence and immunoperoxidase staining features in comparison with lysozyme and lactoferrin. Am. J. Clin. Pathol. 1985, 84, 24–34. [Google Scholar] [CrossRef] [PubMed]
  67. Rugtveit, J.; Brandtzaeg, P.; Halstensen, T.S.; Fausa, O.; Scott, H. Increased macrophage subset in inflammatory bowel disease: Apparent recruitment from peripheral blood monocytes. Gut 1994, 35, 669–674. [Google Scholar] [CrossRef] [Green Version]
  68. Rugtveit, J.; Scott, H.; Halstensen, T.S.; Norstein, J.; Brandtzaeg, P. Expression of the L1 antigen (calprotectin) by tissue macrophages reflects recent recruitment from peripheral blood rather than upregulation of local synthesis: Implications for rejection diagnosis in formalin-fixed kidney specimens. J. Pathol. 1996, 180, 194–199. [Google Scholar] [CrossRef]
  69. Nisapakultorn, K.; Ross, K.; Herzberg, M. calprotectin expression inhibits bacterial binding to mucosal epithelial cells. Infect. Immun. 2001, 69, 3692–3696. [Google Scholar] [CrossRef] [Green Version]
  70. Ghavami, S.; Kerkhoff, C.; Los, M.; Hashemi, M.; Sorg, C.; Karami-Tehrani, F. Mechanism of apoptosis induced by S100A8/A9 in colon cancer cell lines: The role of ROS and the effect of metal ions. J. Leukoc. Biol. 2004, 76, 169–175. [Google Scholar] [CrossRef] [Green Version]
  71. Yui, S.; Mikami, M.; Tsurumaki, K.; Yamazaki, M. Growth-inhibitory and apoptosis-inducing activities of calprotectin derived from inflammatory exudate cells on normal fibroblasts: Regulation by metal ions. J. Leukoc. Biol. 1997, 61, 50–57. [Google Scholar] [CrossRef]
  72. Yui, S.; Mikami, M.; Yamazaki, M. Induction of apoptotic cell death in mouse lymphoma and human leukemia cell lines by a calcium-binding protein complex, calprotectin, derived from inflammatory peritoneal exudate cells. J. Leukoc. Biol. 1995, 58, 650–658. [Google Scholar] [CrossRef] [PubMed]
  73. Voganatsi, A.; Panyutich, A.; Miyasaki, K.T.; Murthy, R.K. Mechanism of extracellular release of human neutrophil calprotectin complex. J. Leukoc. Biol. 2001, 70, 130–134. [Google Scholar] [PubMed]
  74. Sander, J.; Fagerhol, M.K.; Bakken, J.S.; Dale, I. Plasma levels of the leucocyte L1 protein in febrile conditions: Relation to aetiology, number of leucocytes in blood, blood sedimentation reaction and C-reactive protein. Scand. J. Clin. Lab. Invest. 1984, 44, 357–362. [Google Scholar] [CrossRef] [PubMed]
  75. Røseth, A.G.; Fagerhol, M.K.; Aadland, E.; Schjønsby, H. Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scand. J. Gastroenterol. 1992, 27, 793–798. [Google Scholar] [CrossRef] [PubMed]
  76. Røseth, A.G.; Schmidt, P.N.; Fagerhol, M.K. Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. Scand. J. Gastroenterol. 1999, 34, 50–54. [Google Scholar] [PubMed]
  77. Røseth, A.G.; Kristinsson, J.; Fagerhol, M.K.; Schjønsby, H.; Aadland, E.; Nygaard, K.; Roald, B. Faecal calprotectin: A novel test for the diagnosis of colorectal cancer? Scand. J. Gastroenterol. 1993, 28, 1073–1076. [Google Scholar] [CrossRef]
  78. Mulder, D.; Noble, A.; Justinic, C.J.; Duffin, J.M. A tale of two diseases: The history of inflammatory bowel disease. J. Crohn’s Colitis 2014, 8, 341–348. [Google Scholar] [CrossRef] [Green Version]
  79. Kostakis, I.; Cholidou, K.; Vaiopoulos, A.; Vlachos, I.S.; Perrea, D.; Vaos, G. Fecal calprotectin in pediatric inflammatory bowel disease: A systematic review. Dig. Dis. Sci. 2013, 58, 309–319. [Google Scholar] [CrossRef]
  80. D’Angelo, F.; Felley, C.; Frossard, J.L. Calprotectin in daily practice: Where do we stand in 2017? Digestion 2017, 95, 293–301. [Google Scholar] [CrossRef]
  81. Chung-Faye, G.; Hayee, B.; Maestranzi, S.; Donaldson, N.; Forgacs, I.; Sherwood, R. Fecal M2-pyruvate kinase (M2-PK): A novel marker of intestinal inflammation. Inflamm. Bowel Dis. 2007, 13, 1374–1378. [Google Scholar] [CrossRef]
  82. Duvoisin, G.; Lopez, R.N.; Day, A.S.; Lemberg, D.A.; Gearry, R.B.; Leach, S.T. Novel biomarkers and the future potential of biomarkers in inflammatory bowel disease. Mediat. Inflamm. 2017, 2017, 1936315. [Google Scholar] [CrossRef] [PubMed]
  83. Czub, E.; Herzig, K.H.; Szaflarska-Popawska, A.; Kiehne, K.; Socha, P.; Woś, H.; Kamińska, B.; Błaszczyński, M.; Cichy, W.; Bała, G.; et al. Fecal pyruvate kinase: A potential new marker for intestinal inflammation in children with inflammatory bowel disease. Scand. J. Gastroenterol. 2007, 42, 1147–1150. [Google Scholar] [CrossRef]
  84. Day, A.S.; Judd, T.; Lemberg, D.A.; Leach, S.T. Fecal M2-PK in children with Crohn’s disease: A preliminary report. Dig. Dis. Sci. 2012, 57, 2166–2170. [Google Scholar] [CrossRef] [PubMed]
  85. Czub, E.; Nowak, J.K.; Szaflarska-Poplawska, A.; Grzybowska-Chlebowczyk, U.; Landowski, P.; Moczko, J.; Adamczak, D.; Mankowski, P.; Banasiewicz, T.; Plawski, A.; et al. Comparison of fecal pyruvate kinase isoform M2 and calprotectin in assessment of pediatric inflammatory bowel disease severity and activity. Acta Biochim. Pol. 2014, 61, 99–102. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  86. Roszak, D.; Galecka, M.; Cichy, W.; Szachta, P. Determination of faecal inflammatory marker concentration as a non-invasive method of evaluation of pathological activity in children with inflammatory bowel diseases. Adv. Med Sci. 2015, 60, 246–252. [Google Scholar] [CrossRef]
  87. Nahidi, L.; Leach, S.T.; Sidler, M.A.; Levin, A.; Lemberg, D.A.; Day, A.S. Osteoprotegerin in pediatric Crohn’s disease and the effects of exclusive enteral nutrition. Inflamm. Bowel Dis. 2011, 17, 516–523. [Google Scholar] [CrossRef]
  88. Sylvester, F.A.; Turner, D.; Draghi, A.; Uuosoe, K.; McLernon, R.; Koproske, K.; Mack, D.R.; Crandall, W.V.; Hyams, J.S.; LeLeiko, N.S.; et al. Fecal osteoprotegerin may guide the introduction of second-line therapy in hospitalized children with ulcerative colitis. Inflamm. Bowel Dis 2011, 17, 1726–1730. [Google Scholar] [CrossRef] [PubMed]
  89. Vitali, R.; Stronati, L.; Negroni, A.; Di Nardo, G.; Pierdomenico, M.; Del Giudice, E.; Rossi, P.; Cucchiara, S. Fecal HMGB1 is a novel marker of intestinal mucosal inflammation in pediatric inflammatory bowel disease. Am. J. Gastroenterol. 2011, 106, 2029–2040. [Google Scholar] [CrossRef] [PubMed]
  90. Aomatsu, T.; Imaeda, H.; Matsumoto, K.; Kimura, E.; Yoden, A.; Tamai, H.; Fujiyama, Y.; Mizoguchi, E.; Andoh, A. Faecal chitinase 3-like-1: A novel biomarker of disease activity in paediatric inflammatory bowel disease. Aliment. Pharmacol. Ther. 2011, 34, 941–948. [Google Scholar] [CrossRef] [PubMed]
  91. Chen, C.C.; Pekow, J.; Llado, V.; Kanneganti, M.; Lau, C.W.; Mizoguchi, A.; Mino-Kenudson, M.; Bissonnette, M.; Mizoguchi, E. Chitinase 3-like-1 expression in colonic epithelial cells as a potentially novel marker for colitis-associated neoplasia. Am. J. Pathol. 2011, 179, 1494–1503. [Google Scholar] [CrossRef] [PubMed]
  92. Escher, J.C.; Dias, J.A.; Bochenek, K.; Buderus, S.; De Mesquita, M.B.; Bujanover, Y.; Büller, H.A.; Chong, S.K.F.; Cucchiara, S.; Fell, J.M.; et al. IBD Working Group of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition. Inflammatory bowel disease in children and adolescents: Recommendations for diagnosis—the Porto criteria. J. Pediatr. Gastroenterol. Nutr. 2005, 41, 1–7. [Google Scholar]
  93. Levine, A.; Koletzko, S.; Turner, D.; Escher, J.C.; Cucchiara, S.; De Ridder, L.; Kolho, K.L.; Veres, G.; Russell, R.K.; Paerregaard, A.; et al. ESPGHAN revised Porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents. J. Pediatr. Gastroenterol. Nutr. 2014, 58, 795–806. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  94. Turner, D.; Ruemmele, F.M.; Orlanski-Meyer, E.; Griffiths, A.M.; De Carpi, J.M.; Bronsky, J.; Veres, G.; Aloi, M.; Strisciuglio, C.; Braegger, C.P.; et al. Management of paediatric ulcerative colitis, part 1: Ambulatory care-an evidence-based guideline from European Crohn’s and colitis organization and European society of paediatric gastroenterology, hepatology and nutrition. J. Pediatr. Gastroenterol. Nutr. 2018, 67, 257–291. [Google Scholar] [CrossRef] [PubMed]
  95. Turner, D.; Ruemmele, F.M.; Orlanski-Meyer, E.; Griffiths, A.M.; de Carpi, J.M.; Bronsky, J.; Veres, G.; Aloi, M.; Strisciuglio, C.; Braegger, C.P.; et al. Management of paediatric ulcerative colitis, Part 2: Acute severe colitis-an evidence-based consensus guideline from the European Crohn’s and colitis organization and the European society of paediatric gastroenterology, hepatology and nutrition. J. Pediatr. Gastroenterol. Nutr. 2018, 67, 292–310. [Google Scholar] [CrossRef] [PubMed]
  96. Van Rheenen, P.F.; Aloi, M.; Assa, A.; Bronsky, J.; Escher, J.C.; Fagerberg, U.L.; Gasparetto, M.; Gerasimidis, K.; Griffiths, A.; Henderson, P.; et al. The medical management of paediatric Crohn’s disease: An ECCO-ESPGHAN guideline update. J. Crohns Colitis 2020, 7, 1–24. [Google Scholar] [CrossRef]
  97. Waugh, N.; Cummins, E.; Royle, P.; Kandala, N.B.; Shyangdan, D.; Arasaradnam, R.; Clar, C.; Johnston, R. Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: Systematic review and economic evaluation. Health Technol. Assess. 2013, 17, 15–19. [Google Scholar] [CrossRef]
  98. DeRidder, L.; Rings, E.H.; Escher, J.C. Guideline diagnosis and treatment of inflammatory bowel disease in children. Ned. Tijdschr. Voor Geneeskd. 2009, 154, A1898. [Google Scholar]
  99. Bossuyt, P.M.; Irwig, L.; Craig, J.; Glasziou, P. Comparative accuracy: Assessing new tests against existing diagnostic pathways. BMJ 2006, 332, 1089. [Google Scholar] [CrossRef] [Green Version]
  100. Van Rheenen, P.F.; Van de Vijver, E.; Fidler, V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: Diagnostic meta-analysis. BMJ 2010, 341, 3369. [Google Scholar] [CrossRef] [Green Version]
  101. Borkowska, A.; Liberek, A.; Łuczak, G.; Jankowska, A.; Plata-Nazar, K.; Korzon, M.; Kamińska, B. Fecal lactoferrin, a marker of intestinal inflammation in children with inflammatory bowel disease. Acta Biochim. Pol. 2015, 62, 541–545. [Google Scholar] [CrossRef]
  102. Sipponen, T.; Kolho, K.L. Faecal calprotectin in children with clinically quiescent inflammatory bowel disease. Scand. J. Gastroenterol. 2010, 45, 872–877. [Google Scholar] [CrossRef] [PubMed]
  103. McKenna, L.B.; Schug, J.; Vourekas, A.; McKenna, J.B.; Bramswig, N.C.; Friedman, J.R.; Kaestner, K.H. MicroRNAs control intestinal epithelial differentiation, architecture, and barrier function. Gastroenterology 2010, 139, 1654–1664. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  104. Biton, M.; Levin, A.; Slyper, M.; Alkalay, I.; Horwitz, E.; Mor, H.; Kredo-Russo, S.; Avnit-Sagi, T.; Cojocaru, G.; Zreik, F.; et al. Epithelial microRNAs regulate gut mucosal immunity via epithelium-T cell crosstalk. Nat. Immunol. 2011, 12, 239–246. [Google Scholar] [CrossRef] [PubMed]
  105. Peruhova, M.; Peshevska-Sekulovska, M.; Krastev, B.; Panayotova, G.; Georgieva, V.; Konakchieva, R.; Nikolaev, G.; Velikova, T.V. What could microRNA expression tell us more about colorectal serrated pathway carcinogenesis? World J. Gastroenterol. 2020, 26, 6556–6571. [Google Scholar] [CrossRef]
  106. Zahm, A.M.; Hand, N.J.; Tsoucas, D.M.; Le Guen, C.L.; Baldassano, R.N.; Friedman, J.R. Rectal microRNAs are perturbed in pediatric inflammatory bowel disease of the colon. J. Crohn’s Colitis 2014, 8, 1108–1117. [Google Scholar] [CrossRef] [Green Version]
  107. Zahm, A.M.; Thayu, M.; Hand, N.J.; Horner, A.; Leonard, M.B.; Friedman, J.R. Circulating microRNA is a biomarker of pediatric Crohn disease. J. Pediatr. Gastroenterol. Nutr. 2011, 53, 26–33. [Google Scholar] [CrossRef] [Green Version]
Gastroent 11 00009 g001 550
Figure 1. Biomarkers employed in pediatric IBD diagnosing, managing, and follow-up. Along with the conventional non-specific markers for inflammation, there are a great variety of fecal biomarkers that can be easily assessed in fecal samples, and in blood. A promising perspective is assessing microRNA in the mucosa, which alterations can be attributed to IBD, including in the pediatric practice.
Figure 1. Biomarkers employed in pediatric IBD diagnosing, managing, and follow-up. Along with the conventional non-specific markers for inflammation, there are a great variety of fecal biomarkers that can be easily assessed in fecal samples, and in blood. A promising perspective is assessing microRNA in the mucosa, which alterations can be attributed to IBD, including in the pediatric practice.
Gastroent 11 00009 g001
Table
Table 1. Laboratory markers for the pediatric inflammatory bowel disease (IBD) population. Not all proposed biomarkers have validated data on the cut-off, sensitivity, and specificity for detecting intestinal inflammation and disease activity in the pediatric population.
Table 1. Laboratory markers for the pediatric inflammatory bowel disease (IBD) population. Not all proposed biomarkers have validated data on the cut-off, sensitivity, and specificity for detecting intestinal inflammation and disease activity in the pediatric population.
MarkerCut Off ValueSensitivitySpecificityCitation
C-reactive protein5 mg/L51–73%80–93%Waugh et al., 2013 [97]
Erythrocyte sedimentation ratioN/A58–73%80–88%DeRidder et al., 2010 [98]
FibrinogenN/AN/AN/A-
AlbuminN/A31–66%86–98%Bossuyt et al., 2006 [99]
White blood cellsN/AN/AN/A-
Platelet countN/A36–73%81–93%Van Rheenen et al., 2010 [100]
Fecal alpha-1 antitrypsinN/AN/AN/A-
Fecal lactoferrin13 μg/g80.7%92.7%Borkowska et al., 2015 [101]
Fecal calprotectin50–275 μg/g94.4–100%71.9–100%Sipponen et al., 2010 [102]
M2-pyruvate kinase4–5 U/g94.1–97.1%94.3–100%Chung-Faye et al., 2007 [81]
Osteoprotegerin *50 pmol/L 71%69%Sylvester et al., 2011 [88]
High mobility group box protein 1N/AN/AN/A-
Chitinase 3-like 1 13.7 ng/g81.6–84.7%90–100%Aomatsu et al., 2011 [90]
microRNAsN/AN/AN/A-
* Osteoprotegerin in this study is related only to the failure of therapy in severe pediatric ulcerative colitis (UC).
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Shentova-Eneva, R.; Velikova, T. Laboratory Assessment of Disease Activity in Pediatric Patients with Inflammatory Bowel Disease: What’s New? Gastroenterol. Insights 2020, 11, 58-71. https://doi.org/10.3390/gastroent11020009

AMA Style

Shentova-Eneva R, Velikova T. Laboratory Assessment of Disease Activity in Pediatric Patients with Inflammatory Bowel Disease: What’s New? Gastroenterology Insights. 2020; 11(2):58-71. https://doi.org/10.3390/gastroent11020009

Chicago/Turabian Style

Shentova-Eneva, Rayna, and Tsvetelina Velikova. 2020. "Laboratory Assessment of Disease Activity in Pediatric Patients with Inflammatory Bowel Disease: What’s New?" Gastroenterology Insights 11, no. 2: 58-71. https://doi.org/10.3390/gastroent11020009

APA Style

Shentova-Eneva, R., & Velikova, T. (2020). Laboratory Assessment of Disease Activity in Pediatric Patients with Inflammatory Bowel Disease: What’s New? Gastroenterology Insights, 11(2), 58-71. https://doi.org/10.3390/gastroent11020009

Article Metrics

Back to TopTop